Abstract:Protein–protein interactions (PPIs) execute many fundamental cellular functions and have served as prime drug targets over the last two decades. Interfering intracellular PPIs with small molecules has been extremely difficult for larger or flat binding sites, as antibodies cannot cross the cell membrane to reach such target sites. In recent years, peptides smaller size and balance of conformational rigidity and flexibility have made them promising candidates for targeting challenging binding interfaces with satisfactory binding affinity and specificity. Deciphering and characterizing peptide–protein recognition mechanisms is thus central for the invention of peptide-based strategies to interfere with endogenous protein interactions, or improvement of the binding affinity and specificity of existing approaches. Importantly, a variety of computation-aided rational designs for peptide therapeutics have been developed, which aim to deliver comprehensive docking for peptide–protein interaction interfaces. Over 60 peptides have been approved and administrated globally in clinics. Despite this, advances in various docking models are only on the merge of making their contribution to peptide drug development. In this review, we provide (i) a holistic overview of peptide drug development and the fundamental technologies utilized to date, and (ii) an updated review on key developments of computational modeling of peptide–protein interactions (PepPIs) with an aim to assist experimental biologists exploit suitable docking methods to advance peptide interfering strategies against PPIs.

Progress in Small Molecular Inhibitors of Protein-Protein Interactions

Research Progress in Protein-Protein Interactions and Their Inhibitors

Advances of study of protein-protein interactions

Methods to Profile the Macromolecular Targets of Small Compounds.

State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors

Targeting Protein-Protein Interactions: a Promising Avenue of Anti-Hiv Drug Discovery.

Small molecules targeting protein‒protein interactions for cancer therapy

Targeting Protein-Protein Interaction by Small Molecules

Rational Design of Small-sized Peptidomimetic Inhibitors Disrupting Protein-Protein Interaction

Protein-Protein Interaction: Prediction, Design, and Modulation

Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis.

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

Main methods and tools for peptide development based on protein-protein interactions (PPIs)

Progress in Design of Protein-Protein Interface

Peptide-based inhibitors of protein–protein interactions: biophysical, structural and cellular consequences of introducing a constraint

The Research Progress of Protein-Protein Interactions in Bioinformatics

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Recent Developments In Engineering Protein-Protein Interactions Using Phage Display

A Comprehensive Review on Current Advances in Peptide Drug Development and Design

Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery